Prof Samuel Janes

University College London Hospitals
Professor of respiratory medicine

Professor Samuel Janes qualified in 1992 gaining a BSc and MBBS. He trained in respiratory medicine at several hospitals including the Hammersmith, Harefield and St Mary’s Hospitals and completed an MSc (Distinction) in Respiratory Medicine in 1999 at the Brompton Hospital. He gained his CCST in Respiratory and General Medicine in 2004. He won a MRC Training Fellowship and worked in the CRUK Lincoln’s Inn Fields Institute with Fiona Watt working on integrin adhesion molecules and cancer cell survival leading to his PhD in 2004. He then worked as a post-doctoral fellow at the same institute before moving to University College London. At UCL he won an MRC Clinician Scientist Fellowship and now leads a group interested in the pathogenesis of lung disease including cancer formation and its treatment with new biological and cellular therapies within the Centre for Respiratory Research. He has a particular interest in using stem cells as a cellular vector for gene therapy in cancers.

dont miss

Coming soon

Coming soon

EVEN MORE SEMINARS

  • John Watkinson, MBBS, FRCS, DLO, MSc: Speaking at the Oncology Convention

    John Watkinson, MBBS, FRCS, DLO, MSc
    BUPA Cromwell Hospital

    Consultant ENT Surgeon

  • Glenn Flux: Speaking at the Oncology Convention

    Glenn Flux
    Royal Marsden Hospital

    The emergence and resurgence of radiotherapeutics for cancer treatment

  • Dr Ioanna Nixon: Speaking at the Oncology Convention

    Dr Ioanna Nixon
    Beatson West of Scotland Cancer center, NHS Greater Glasgow and Clyde

    When the oncologist meets the patient: value of compassion. How well are we doing?

  • Dr Ndaba Mazibuko: Speaking at the Oncology Convention

    Dr Ndaba Mazibuko
    Care Oncology Clinic, Kings College London

    Drug Repurposing In Practice: Metabolic Pleiotropism in Glioblastoma Management

  • Professor A. Graham Pockley: Speaking at the Oncology Convention

    Professor A. Graham Pockley
    multimmune GmbH / Nottingham Trent University

    A new era of cancer therapeutics?